SCHEMBL2371226

SCHEMBL2371226

O=c1c2cc(-c3cccnc3F)ccc2oc2c(F)nc(Br)cc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 4/20 0.36
CYP11B2 P19099 1/20 0.36
MAPT P10636 1/20 0.36
METAP2 P50579 2/20 0.34
DYRK1A Q13627 1/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
BACE1 P56817 6/20 0.33
CTSD P07339 2/20 0.33
PIM1 P11309 1/20 0.32
CSNK2A2 P19784 1/20 0.32
CSNK2B P67870 1/20 0.32
PIM3 Q86V86 1/20 0.32
PIM2 Q9P1W9 1/20 0.32
CYP2C19 P33261 1/20 0.32
GRIA2 P42262 1/20 0.32
CASP3 P42574 1/20 0.32
SENP7 Q9BQF6 1/20 0.32
SENP6 Q9GZR1 1/20 0.32
NCOA1 Q15788 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2371025 0.75 CYP11B2 (0.43) DHODHCYP11B2MAPTMETAP2DYRK1A
SCHEMBL2371193 0.73 MAPT (0.38) DHODHCYP11B2MAPTMETAP2DYRK1A
SCHEMBL2371100 0.71 BACE1 (0.42) MAPTMETAP2DYRK1ABACE1CTSD
SCHEMBL2370555 0.68 KDM4E (0.36) DHODHMETAP2DYRK1AKDM4EALDH1A1
SCHEMBL571166 0.66 PIM1 (0.45) PIM1CSNK2A2CSNK2BPIM3PIM2
SCHEMBL2371067 0.65 BACE1 (0.43) CYP11B2BACE1CTSD
SCHEMBL12181809 0.65 ALOX5 (0.62) MAPTKDM4EALDH1A1CASP3SENP7
SCHEMBL2370701 0.64 CSNK2B (0.38) KDM4EPIM1CSNK2A2CSNK2BPIM3
SCHEMBL26936212 0.63 TTR (0.39) MAPTKDM4EALDH1A1CASP3SENP7
SCHEMBL10055194 0.63 ALOX5 (0.59) MAPTKDM4EALDH1A1CASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883782-B2 Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-11-11 US disclosed
EP-2547685-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS Amgen Inc. (US) 2013-01-23 EP disclosed
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-10-13 US disclosed
WO-2011115938-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS AMGEN INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP DHODH 1586/4885CYP11B2 1818/4885MAPT 753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.